^
    Back
    Association details:
    Biomarker:RET amplification
    Cancer:Non Small Cell Lung Cancer
    Drug:Retevmo (selpercatinib) (RET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    ASCO 2023
    Title:

    Amplification of wild-type RET and clinical response to selpercatinib for non–small-cell lung cancer (NSCLC).

    Published date:
    05/25/2023
    Excerpt:
    A 69-year-old man with unresectable stage III NSCLC had disease recurrence after chemoradiation and durvalumab. Both the initial and recurrent biopsy samples showed focal high-level RET amplification (22 and 28 copies, respectively)...He experienced partial response to the selective RET inhibitor selpercatinib with decrease of both intracranial and systemic tumor burden.
    DOI:
    10.1200/JCO.2023.41.16_suppl.9123